In the largest genetic study of fibromyalgia ever conducted, 47,895 of 54,629 patients, or 87.7 percent, were female. The condition affects roughly 2 percent of people worldwide, and that lopsided ratio has been one of its defining features for as long as it has been recognized.
So the researchers did the obvious thing. They split the data by sex and looked for genetic differences that might explain the gap.
They found none, essentially. Despite the large difference in prevalence, the genetic architecture of fibromyalgia was nearly identical between males and females. Whatever is producing that diagnostic ratio, according to the study published in Nature Medicine, it does not appear to be common genetic variation.
A Negative Result That Says Something
The study analyzed 2,563,755 people across 11 cohorts in the United States, United Kingdom, Finland, Estonia, Denmark and Iceland, comprising 54,629 cases and 2,509,126 controls, and identified 26 genetic risk loci. Before this, as the authors note, the GWAS Catalog listed no prior genetic associations with fibromyalgia.
The 26 loci and the drug targets among them drew most of the attention when the paper appeared. The sex analysis is the quieter finding, and arguably the one with sharper consequences for patients sitting in waiting rooms.
If men and women carry the same genetic liability at similar strength, then a diagnosis rate skewed heavily toward women points somewhere other than DNA. The candidates are non-genetic biology such as hormonal or immune differences, environmental exposures, or bias in how the condition gets recognized and recorded.
One number in the paper makes that last possibility hard to dismiss. Recorded prevalence varied roughly sixfold across the 11 cohorts, from 1.2 percent in the Estonian Biobank to 7.5 percent in the Michigan Genomics Initiative, with a median of 2.5 percent. Populations do not differ that much. Diagnostic practice apparently does.
The study cannot distinguish between the remaining explanations. It is a genetic analysis, and its power ends where genetics ends. But it does narrow the field by ruling out one explanation that had seemed plausible.
There is a caveat that cuts both ways. Cases were identified from health records using the ICD-10 code M79.7 in inpatient or primary care data, meaning the study measured who received a fibromyalgia diagnosis, not who had the underlying condition. If men with fibromyalgia are systematically under-recognized, some of them are sitting in the control group. That would tend to blur signals rather than manufacture a false match between the sexes.
The Condition Keeps Overlapping With Other Contested Diagnoses
The genetic correlations tell a related story. Fibromyalgia showed correlations above 0.7 with low back pain, post-traumatic stress disorder and irritable bowel syndrome, which is very high for distinct clinical labels.
Genetic overlap with autoimmune conditions, by contrast, was modest and aligned more closely with seronegative rheumatoid arthritis than with seropositive rheumatoid arthritis. Heritability was enriched exclusively in brain tissues and neural cell types, which the researchers treat as evidence that fibromyalgia is primarily a central nervous system disorder rather than an autoimmune one, consistent with the central sensitization model in which altered neural processing amplifies pain.
The strongest single signal was a coding variant in HTT, the gene responsible for Huntington's disease, though it is far from the repeat expansion that causes it. Other prioritized genes included GPR52, DCC, DRD2/NCAM1, MDGA2, and CELF4, most of which have roles in neural development or pain processing. The full results are available in an open-access version for readers who want the underlying numbers, and are indexed in PubMed. The findings first appeared as a preprint before peer review.
What This Does and Does Not Change for Patients
Nothing about diagnosis or treatment changes today. There is no genetic test for fibromyalgia, and none is coming from this work. A polygenic risk score built from the data statistically separated groups, with recorded prevalence among European-ancestry participants rising from about 1.0 percent in the lowest fifth to 2.4 percent in the highest, but that is a population-level signal and useless for telling any individual whether they have the condition.
The practical value is different. Fibromyalgia has spent decades being questioned as a real illness, in part because it lacks a biomarker. A study of this size finding a reproducible genetic signal enriched in brain tissue, led in part by Fred Hutch Cancer Center with 53 researchers across seven countries, makes that argument harder to sustain.
Two limits are worth stating. Roughly 90 percent of cases were of European ancestry, and the researchers ran European-only analyses precisely because of that imbalance, so it remains unclear how well these findings extend to other populations. And a genetic association is not a mechanism; identifying a locus is a starting point for biology, not a finished explanation.
Anyone with unexplained widespread pain, fatigue, and sleep problems should be evaluated by a clinician. This research does not alter what that evaluation looks like, but it may change how seriously the resulting diagnosis is taken.
Key Questions Answered
What did the sex analysis actually show?
Despite women making up 87.7 percent of cases, the genetic architecture of fibromyalgia was nearly identical in men and women.
So why are so many more women diagnosed?
The study cannot answer that. It rules out common genetic variation and points toward non-genetic biology, environmental factors, or bias in how the condition is recognized and recorded.
Does this mean men are being missed?
It is one possible explanation, alongside others. Because cases were identified from diagnostic codes, under-recognized men would be counted as controls.
Is there now a genetic test for fibromyalgia?
No. The polygenic risk score can statistically separate groups but cannot diagnose an individual, and no test is available or in development for clinical use.
Why do the genetics overlap with PTSD and IBS?
Genetic correlations above 0.7 suggest shared central nervous system biology. This may reflect real comorbidity, misdiagnosis, or a common underlying vulnerability.
What does this mean for someone living with fibromyalgia?
Treatment does not change. The evidence strengthens the case that fibromyalgia has a measurable biological basis in the nervous system, which matters for a condition long met with skepticism.
